Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Time for a new uptick, running leg Up

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Oct 12, 2021 2:56pm

229 Views

Post# 33998307

RE:Time for a new uptick, running leg Up

agreed for the most part and we can only hope that the company does not sell too much into the ATM on any signs of recovery as this would limit our upside as has been shown in the past.
At this time the ATM is their lifeline and hope they use it accordingly.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management